一个随机的混合型I型有效性-实施研究的eHealth交付替代癌症遗传癌症的基因检测 (eREACH2):研究协议
medRxiv : the preprint server for health sciences
|December 3, 2025
概括
在eREACH 2研究中,将数字基因测试方法与传统咨询进行了比较,发现数字方法在增加遗传性癌症基因测试的普及方面不逊色. 这种创新模式改善了风险患者获得遗传服务的机会.
科学领域:
- 遗传学 遗传学 是一个
- 在瘤学瘤学.
- 数字健康数字健康
背景情况:
- 生殖系癌症遗传检测对于降低风险,查和向治疗至关重要.
- 获得遗传服务仍然是一个重要的障碍,导致未识别的遗传载体.
- 通过评估遗传检测的数字替代方案,eREACH 2研究解决了这一差距.
研究的目的:
- 评估数字化,以患者为中心的基因教育和结果披露的替代方案是否与传统的遗传咨询相匹配.
- 评估创新的交付模式的有效性,以提高基因服务的普及率.
主要方法:
- 一个混合型1有效性实施研究,采用2x2随机设计.
- 参与者被随机分配,接受遗传咨询和/或进行测试前和测试后咨询的数字干预.
- 主要结局包括基因测试吸收的非劣势,遗传知识的变化和一般焦虑.
主要成果:
- 在采用基因测试方面,数字干预被发现与传统遗传咨询无差.
- 该研究评估了基因知识和一般焦虑的变化,从基线到披露后.
结论:
- 需要创新的交付模式,例如eREACH 2中评估的数字干预,以克服遗传服务的障碍.
- 这种数字化方法有可能为基于证据的指导方针和遗传测试提供护理标准提供信息.
- 这些发现在瘤学之外广泛适用,可能扩展到阿尔茨海默病等其他疾病.
更多相关视频
11:34Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers
Published on: December 5, 2017
13.0K
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
7.8K
相关概念视频
02:50Combination Therapies and Personalized Medicine
5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K
01:12Hazard Ratio
549
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
For example, in a clinical trial...
549